Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marta Tonon

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Alimentary Pharmacology & Therapeutics|November 22, 2023
The polymorphic variant of SerpinB3 (SerpinB3-PD) is associated with faster cirrhosis decompensationAndrea Martini, Cristian Turato, Stefania Cannito, et al.
JHEP Reports : Innovation in Hepatology|July 17, 2025
Risk of portal hypertensive complications preventable by TIPS in patients with ascitesLorenz Balcar, Marta Tonon, Joan Valls, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 19, 2026
Personalised Long-Term Albumin Treatment Based on Three-Month Ascites Response in Patients With Decompensated CirrhosisEnrico Pompili, Giulia Iannone, Salvatore Piano, et al.
Hepatology (Baltimore, Md.)|May 16, 2023
Etiological cure prevents further decompensation and mortality in patients with cirrhosis with ascites as the single first decompensating eventMarta Tonon, Lorenz Balcar, Georg Semmler, et al.
Journal of Viral Hepatitis|May 11, 2026
Effectiveness, Safety and Patient-Reported Outcomes of Bulevirtide Therapy in Chronic Hepatitis Delta: Real-World Evidence From a Prospective Observational StudyDaniele Mengato, Sara Battistella, Alessandro Cadore, et al.
Alimentary Pharmacology & Therapeutics|July 28, 2025
Refining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non-Acute DecompensationLucie Simonis, Lorenz Balcar, Anna Schedlbauer, et al.
JHEP Reports : Innovation in Hepatology|December 6, 2024
Real-world experience with long-term albumin in patients with cirrhosis and ascitesEnrico Pompili, Giacomo Zaccherini, Salvatore Piano, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 3, 2018
Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal SyndromeSalvatore Piano, Hartmut H Schmidt, Xavier Ariza, et al.
JHEP Reports : Innovation in Hepatology|April 6, 2026
Impact of Hepatocellular Carcinoma on the risk of liver decompensation: a comparative analysis of patients with and without HCC: Role of HCC in liver decompensationAndrea Martini, Massimo Iavarone, Roberta D'Ambrosio, et al.
Hepatology Communications|December 29, 2021
Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated CirrhosisElisa Pose, Elsa Solà, Juan J Lozano, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Alimentary Pharmacology & Therapeutics|November 22, 2023
The polymorphic variant of SerpinB3 (SerpinB3-PD) is associated with faster cirrhosis decompensationAndrea Martini, Cristian Turato, Stefania Cannito, et al.
JHEP Reports : Innovation in Hepatology|July 17, 2025
Risk of portal hypertensive complications preventable by TIPS in patients with ascitesLorenz Balcar, Marta Tonon, Joan Valls, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 19, 2026
Personalised Long-Term Albumin Treatment Based on Three-Month Ascites Response in Patients With Decompensated CirrhosisEnrico Pompili, Giulia Iannone, Salvatore Piano, et al.
Hepatology (Baltimore, Md.)|May 16, 2023
Etiological cure prevents further decompensation and mortality in patients with cirrhosis with ascites as the single first decompensating eventMarta Tonon, Lorenz Balcar, Georg Semmler, et al.
Journal of Viral Hepatitis|May 11, 2026
Effectiveness, Safety and Patient-Reported Outcomes of Bulevirtide Therapy in Chronic Hepatitis Delta: Real-World Evidence From a Prospective Observational StudyDaniele Mengato, Sara Battistella, Alessandro Cadore, et al.
Alimentary Pharmacology & Therapeutics|July 28, 2025
Refining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non-Acute DecompensationLucie Simonis, Lorenz Balcar, Anna Schedlbauer, et al.
JHEP Reports : Innovation in Hepatology|December 6, 2024
Real-world experience with long-term albumin in patients with cirrhosis and ascitesEnrico Pompili, Giacomo Zaccherini, Salvatore Piano, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 3, 2018
Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal SyndromeSalvatore Piano, Hartmut H Schmidt, Xavier Ariza, et al.
JHEP Reports : Innovation in Hepatology|April 6, 2026
Impact of Hepatocellular Carcinoma on the risk of liver decompensation: a comparative analysis of patients with and without HCC: Role of HCC in liver decompensationAndrea Martini, Massimo Iavarone, Roberta D'Ambrosio, et al.
Hepatology Communications|December 29, 2021
Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated CirrhosisElisa Pose, Elsa Solà, Juan J Lozano, et al.
Pageof 6